{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T22:39:33Z","timestamp":1785278373743,"version":"3.55.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":396,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pain Med"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1111\/pme.12330","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T17:51:55Z","timestamp":1389203515000},"page":"1282-1293","source":"Crossref","is-referenced-by-count":3,"title":["Potential Drug\u2013Drug and Drug\u2013Condition Interactions among Fibromyalgia Patients Initiating Pregabalin or Duloxetine: Prevalence and Health Care Expenditure Impact"],"prefix":"10.1093","volume":"15","author":[{"given":"Stephen S.","family":"Johnston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Udall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C.","family":"Cappelleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara H.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Shrady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bong-Chul","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart L.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,8,1]]},"reference":[{"key":"2016012001043647000_15.8.1282.1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2011.595734"},{"key":"2016012001043647000_15.8.1282.2","first-page":"151","article-title":"Aspects of fibromyalgia in the general population: Sex, pain threshold, and fibromyalgia symptoms","volume":"22","author":"Wolfe","year":"1995","journal-title":"J Rheumatol"},{"key":"2016012001043647000_15.8.1282.3","doi-asserted-by":"crossref","unstructured":"Fitzcharles M Ste-Marie PA Goldenberg DL 2012 Canadian Guidelines for the Diagnosis and Management of Fibromyalgia Syndrome. Available at: http:\/\/www.canadianpainsociety.ca\/pdf\/Fibromyalgia_Guidelines_2012.pdf (accessed December 2012).","DOI":"10.1155\/2013\/918216"},{"key":"2016012001043647000_15.8.1282.4","unstructured":"Lyrica. New York, NY: Pfizer Inc. 2012."},{"key":"2016012001043647000_15.8.1282.5","unstructured":"Cymbalta. Indianapolis, IN: Eli Lilly and Company. 2012."},{"key":"2016012001043647000_15.8.1282.6","unstructured":"Savella. New York, NY: Forrest Laboratories, Inc. 2012."},{"key":"2016012001043647000_15.8.1282.7","unstructured":"Truven Health Analytics. Unpublished Data from the MarketScan Commercial and Medicare Supplemental Databases. 2012."},{"key":"2016012001043647000_15.8.1282.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540280039031"},{"key":"2016012001043647000_15.8.1282.9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540280045032"},{"key":"2016012001043647000_15.8.1282.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03628.x"},{"key":"2016012001043647000_15.8.1282.11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.18433\/J35C7Z","article-title":"Drug-drug interactions associated with length of stay and cost of hospitalization","volume":"12","author":"Moura","year":"2009","journal-title":"J Pharm Pharm Sci"},{"key":"2016012001043647000_15.8.1282.12","doi-asserted-by":"publisher","DOI":"10.1007\/BF03256929"},{"key":"2016012001043647000_15.8.1282.13","first-page":"e1","article-title":"Clinical and economic outcomes associated with potentially inappropriate prescribing in the elderly","volume":"16","author":"Stockl","year":"2010","journal-title":"Am J Manag Care"},{"key":"2016012001043647000_15.8.1282.14","unstructured":"Micromedex\u00ae Medication Management. Information. 2012. Available at: http:\/\/www.truvenhealth.com\/your_healthcare_focus\/hospital_patient_care_decisions\/medication_management.aspx (accessed December 2012)."},{"key":"2016012001043647000_15.8.1282.15","unstructured":"Consumer Price Index (CPI)\u2014Bureau of Labor Statistics. 2012. Available at: http:\/\/www.bls.gov\/cpi\/ (accessed December 2012)."},{"key":"2016012001043647000_15.8.1282.16","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2010.535878"},{"key":"2016012001043647000_15.8.1282.17","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2011.650773"},{"key":"2016012001043647000_15.8.1282.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2010.00440.x"},{"key":"2016012001043647000_15.8.1282.19","unstructured":"Glick HA Doshi JP Sonnad SS Polsky D . Economic Evaluation in Clinical Trials. New York: Oxford University Press; 2007."},{"key":"2016012001043647000_15.8.1282.20","doi-asserted-by":"crossref","unstructured":"Jones AM Rice N Bago d'Eva T Balia S . Applied Health Economics, 2nd edition. New York: Routledge; 2013.","DOI":"10.4324\/9780203102411"},{"key":"2016012001043647000_15.8.1282.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-6296(01)00086-8"},{"key":"2016012001043647000_15.8.1282.22","doi-asserted-by":"publisher","DOI":"10.2307\/2288126"},{"key":"2016012001043647000_15.8.1282.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-6773.2008.00900.x"},{"key":"2016012001043647000_15.8.1282.24","doi-asserted-by":"crossref","unstructured":"Sadosky A Berger A Zlateva G Oster G . Identification of Fibromyalgia Patients who may not be Appropriate Candidates for Duloxetine or Pregabalin Therapy. American Pain Society Annual Scientific Meeting, May 7\u20139. 2009. Poster #274.","DOI":"10.1016\/j.jpain.2009.01.183"},{"key":"2016012001043647000_15.8.1282.25","unstructured":"Institute for Safe Medication Practices. QuarterWatch. Monitoring FDA MedWatch Reports. Anticoagulants the Leading Reported Drug Risk in 2011. May 31, 2012. New Data from 2011 Quarters 3\u20134. 2012. Available at: http:\/\/www.ismp.org\/quarterwatch\/pdfs\/2011Q4.pdf. (accessed August 2012)."},{"key":"2016012001043647000_15.8.1282.26","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3111\/13696998.2011.583302","article-title":"Economic impact of potential drug-drug interactions in opioid analgesics","volume":"14","author":"Summers","year":"2011","journal-title":"J Med Econ"},{"key":"2016012001043647000_15.8.1282.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2011.00503.x"},{"key":"2016012001043647000_15.8.1282.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2011.00498.x"},{"key":"2016012001043647000_15.8.1282.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61092-7"}],"container-title":["Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/painmedicine\/article-pdf\/15\/8\/1282\/5305754\/15-8-1282.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:37:18Z","timestamp":1647909438000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/painmedicine\/article-lookup\/doi\/10.1111\/pme.12330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2014,8,1]]},"published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.1111\/pme.12330"],"URL":"https:\/\/doi.org\/10.1111\/pme.12330","relation":{},"ISSN":["1526-2375","1526-4637"],"issn-type":[{"value":"1526-2375","type":"print"},{"value":"1526-4637","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8]]}}}